New drug ST-001 tested in lung cancer patients who have run out of options
NCT ID NCT06922539
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called ST-001 in people with small cell lung cancer that has returned or not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 44 participants will receive the drug through an IV for five days every three weeks. Researchers will also watch for any signs that the drug is shrinking tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Southern California
RECRUITINGLos Angeles, California, 90007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.
- Experimental drug duo aims to boost immune attack on tough cancers
- Pinpoint radiation may spare the brain in lung cancer that spreads
- Rapid autopsy program aims to unlock secrets of aggressive lung cancer
- Mapping Cancer's evolution: a study to outsmart treatment resistance